| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Ardelyx Inc. | IBSRELA (tenapanor) - (ACCEL) | Chronic idiopathic constipation (CIC) | Phase 3 | Enrollment Initiation | Oral | Gastroenterology |
| Ardelyx Inc. | Tenapanor - (AMPLIFY) | Hyperphosphatemia - adjunctive therapy to phosphate binders | Phase 3 | Data Released | Oral | N/A |
| Ardelyx Inc. | Tenapanor - (AMPLIFY) | Hyperphosphatemia - adjunctive therapy to phosphate binders | Phase 3 | Data Released | Oral | N/A |
| Ardelyx Inc. | Tenapanor - (T3MPO-1) | Constipation-predominant irritable bowel syndrome (IBS-C) | Phase 3 | Trial Completed | Oral | Gastroenterology |
| Ardelyx Inc. | Tenapanor - (T3MPO-1) | Constipation-predominant irritable bowel syndrome (IBS-C) | Phase 3 | Trial Completed | Oral | Gastroenterology |
| Arena Pharmaceuticals Inc. | SENS-401 | Cisplatin-Induced Ototoxicity | Phase 2a | Ongoing | Oral | Oncology |
| argenx SE | VYVGART - (ADAPT SERON) | Myasthenia Gravis | PDUFA | Ongoing | Intravenous | Neurology |
| argenx SE | Efgartigimod (ARGX-113) - (ADDRESS) | Pemphigus foliaceous and vulgaris (PV) | Phase 3 | Data Released | Intravenous | Immunology |